Last fetch attempt was insuccessful.
Reason: Timeout was reached
-
21 May ' 00:22
May 21, 2012 -
20 May ' 02:53
May 20, 2012WASHINGTON, May 17, 2012 — Despite increasing budget pressures, countries around the world are making substantial investments in pro-innovation policies and programs to lure the biopharmaceutical research sector away from the U.S., finds a new study released by Battelle Technology Partnership Practice.SILVER SPRING, Md., May 17 2012-- The U.S. Food and Drug Administration today approved generic versions of the blood thinning drug Plavix (clopidogrel bisulfate), which helps reduce the risk of heart attack and stroke by making it less likely that platelets in the blood will clump and form clots in the arteries.NEW YORK, May 17, 2012 (AP) -- Osiris Therapeutics Inc. said Thursday that Canadian regulators approved its stem cell therapy Prochymal, which is intended to treat a deadly side effect of bone marrow transplants.
PARSIPPANY, N.J., May 18, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc., a leading specialty global pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference on Wednesday, May 30, 2012 at 4:00PM Eastern Time at the Waldorf-Astoria Hotel in New York, New York.HAWTHORNE, N.Y.--(BUSINESS WIRE)--May 18, 2012 - Taro Pharmaceutical Industries Ltd., announced today that it will release its financial results for the quarter ended March 31, 2012 after market close on Thursday, May 24, 2012.MONT-SAINT-GUIBERT, Belgium, May 18, 2012/PRNewswire/ --The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces that the final results of its Phase II clinical trial of C3BS-CQR-1 is will be presented at the late breaking clinical trial session at the European Society of Cardiology 2012 Heart Failure Congress in Belgrade, Serbia taking place on May 19-22.COLUMBUS, Ohio--(BUSINESS WIRE)--May 18, 2012 - Ohio's bioscience industry is in growth mode. Proof (and jobs) will be on display at BioOhio's May 23 Biomedical & Pharma Career Fair in Columbus.BETHLEHEM, Pa., May 18, 2012 /PRNewswire/ -- Digestive Care, Inc. (DCI), announced that the company has received U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for PERTZYE, indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis (CF) or other conditions.PHILADELPHIA, May 18, 2012/PRNewswire/ -- Migraine Meter, a free mobile app to help patients manage and monitor their migraines launched today by Health Union, LLC.It looks to be a relatively quiet American Society of Clinical Oncology (ASCO) meeting this year, judging by Wall Street’s sedate reaction to Wednesday evening’s abstract dump, an event that usually sends stocks jumping while analysts and investors scramble to keep up.PARSIPPANY, N.J., May 18, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl Estradiol and Ferrous Fumarate Tablets,1 mg/0.01 mg and 0.01 mg and 75 mg.NEW YORK, May 18, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. announces that Dr. Daniel G. Chain, the company's chairman and CEO, will be presenting at the Seventh Annual Neurotech Investing and Partnering Conference.PITTSBURGH and NEW YORK, May 18, 2012 /PRNewswire/ -- The Drug Store News Group, the Pharmacist Society and Mylan Inc., one of the world's leading generics and specialty pharmaceutical companies, are pleased to announce an exclusive sponsorship to expand membership opportunities at PharmacistSociety.com – an online forum that supports and enhances professional networks for U.S.-based retail pharmacists, professional organizations and pharmacy companies.WASHINGTON--(BUSINESS WIRE)--May 18, 2012 - Building on its recent testimony to the FDA on modernizing clinical trials, the Association of Clinical Research Organizations (ACRO) has released a new video exhorting the FDA to demonstrate “bold leadership” to help make the drug development process less expensive, faster and more productive.ATLANTA, May 18, 2012 /PRNewswire/ -- UCB, Inc., a leading biopharmaceutical company dedicated to the research and development of treatments for severe central nervous system and immunological disorders, is marking Digestive Disease Week (DDW) 2012 in San Diego by reinforcing its commitment to improving the lives of patients with Crohn's disease. UCB will present scientific data at this year's DDW meeting.MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--May 18, 2012 - Medgenics, Inc., the developer of the novel Biopump technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Andrew L. Pearlman, Ph.D., the Company's President and CEO, will present a corporate overview at the 11th Annual Israeli Life Sciences Industry Biomed 2011 Conference taking place at the David Intercontinental Hotel in Tel Aviv, Israel from May 21-23, 2012.TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--May 18, 2012 - Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that an abstract reporting new data from the BiovaxID Phase II mantle cell lymphoma clinical trial conducted by the U.S. National Cancer Institute (NCI) is now available on-line with the significance of these results to be presented by the NCI at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO 2012).INDIANAPOLIS--(BUSINESS WIRE)--May 18, 2012 - Novo Nordisk, a world leader in diabetes care, announced today that it has expanded its motorsports initiatives to include an official partnership with INDYCAR.NEEDHAM, Mass.--(BUSINESS WIRE)--May 18, 2012 - Celldex Therapeutics, Inc. will host a conference call at 4:30 P.M. Eastern Time on Wednesday, May 23, 2012 to announce interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer.STAMFORD, Conn., May 18, 2012 /PRNewswire/ -- Purdue Pharma L.P. will present an analysis of data from completed clinical trials for Butrans (buprenorphine) Transdermal System CIII at the American Pain Society's (APS) 31st Annual Scientific Meeting.LUND, Sweden & PARIS--(BUSINESS WIRE)--May 18, 2012 -Active Biotech and Ipsen will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference “2012 ASCO Annual Meeting” to be held in Chicago (USA) on 1-5 June 2012.WORCESTER, Mass. and TORONTO, May 18, 2012 /PRNewswire/ -- Generex Biotechnology Corporation announced today that additional members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., for the company's AE37 breast cancer vaccine.CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2012 - InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that CEO Frank Reynolds is scheduled to appear on KXAN-TV's Austin News Today Weekend on Saturday, May 19th at 7:20am CDT in Austin, TX.NEW YORK--(BUSINESS WIRE)--May 18, 2012 - Forest Laboratories, Inc. and Almirall, S.A. today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic Society (ATS) International Conference scheduled May 18 - 23 in San Francisco, CA.VIENNA, Va.--(BUSINESS WIRE)--May 18, 2012 - The following letter was provided to shareholders by CEL-SCI Corporation for today's annual shareholder meeting:MORRISTOWN, N.J., May 18, 2012 /PRNewswire/ -- Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg and 12mg, a generic equivalent to GlaxoSmithKline's Requip XL.NEW YORK--(BUSINESS WIRE)--May 18, 2012 - New York Biotechnology Association (NYBA), the voice of New York State's bioscience industry, today announced that the 2012 honorees of the Association's annual leadership awards will be the leaders of Regeneron Pharmaceuticals, New York's largest biotechnology company: Dr. Leonard Schleifer, MD, PhD, founder, president and CEO, and Dr. George Yancopoulos, MD, PhD, founding scientist, president, Regeneron Laboratories and Chief Scientific Officer.RARITAN, N.J., May 18, 2012 /PRNewswire/ -- Data related to ZYTIGA (abiraterone acetate) clinical studies have been selected for presentation at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).NEW YORK, May 18, 2012 /PRNewswire/ -- The American Society of Hypertension (ASH) opens its 27th Annual Scientific Meeting on Saturday, May 19, 2012 at the Hilton in New York City.MARLBOROUGH, Mass.--(BUSINESS WIRE)--May 18, 2012 - Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that chairman and CEO Gary Rabin will be presenting at the World Stem Cells and Regenerative Medicine Conference, May 21-23, in London.SAN DIEGO, May 18, 2012 /PRNewswire/ -- Receptos Inc. today announced that company personnel will deliver a scientific podium presentation about RPC1063 at the Digestive Disease Week (DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 at the San Diego Convention Center in San Diego, California.SAN DIEGO--(BUSINESS WIRE)--May 18, 2012 - Santarus, Inc. today announced that safety and efficacy data from a Phase III, double-blind, multicenter, placebo-controlled 12 month extended use study with the investigational drug UCERIS (budesonide) 6 mg tablets (previously referred to as budesonide MMX) will be featured in four poster presentations at the Digestive Disease Week (DDW) Meeting being held at the San Diego Convention Center on May 19 – 22, 2012.NEW YORK--(BUSINESS WIRE)--May 18, 2012 - Pfizer Inc. announced today the results of studies on Lyrica (pregabalin) capsules CV presented at the American Pain Society Annual Meeting in Honolulu.HYDERABAD, India--(BUSINESS WIRE)--May 18, 2012 - Dr. Reddy's Laboratories announced today that it has launched CLOPIDOGREL TABLETS, USP 75 mg & 300 mg, a bioequivalent generic version of PLAVIX, in the U.S. market on May 18, 2012.BILLERICA, Mass.--(BUSINESS WIRE)--May 18, 2012 - Bruker Corporation announced today that it will host its Inaugural Analyst Day on Friday, June 1st, from 8:30 a.m. to 11:30 a.m. Eastern Daylight Time, at the InterContinental New York Barclay Hotel, 111 East 48th Street, in New York City.RALEIGH, N.C.--(BUSINESS WIRE)--May 18, 2012 - Salix Pharmaceuticals, Ltd. today announced that numerous presentations and educational activities related to the investigation of several of the Company's products or relevant disease states are scheduled to take place during Digestive Disease Week DDW 2012.NEW YORK & PARIS--(BUSINESS WIRE)--May 18, 2012 - Bionest Partners, a premier strategy and management consulting firm for the life science industries, and a recognized leader in personalized medicine (PM) strategy consulting, announces the publication of an article in a recent issue of Nature Reviews Drug Discovery (NRDD).WOBURN, Mass. & TOKYO--(BUSINESS WIRE)--May 18, 2012 - ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that recruitment of patients has been completed in the randomized, double-blind, controlled Phase 3 MARQUEE pivotal trial of their investigational selective c-MET inhibitor, tivantinib, in combination with erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC). -
17 May ' 22:58
May 18, 2012LOS ANGELES--(BUSINESS WIRE)--May 17, 2012 - Cornerstones Health Inc., a nonprofit organization working to improve communication between patients with inflammatory bowel disease (IBD) and physicians who treat IBD, in collaboration with Imedex, LLC and Mechanisms in Medicine Inc., announced the launch of the new YouTube “You and IBD” - Animated IBD Patient Channel.NATICK, Mass., May 17, 2012 /PRNewswire/ -- Boston Scientific Corporation announces U.S. Food and Drug Administration approval and market launch of the Epic Vascular Self-Expanding Stent System.ROCKVILLE, Md.--(BUSINESS WIRE)--May 17, 2012 - Emergent BioSolutions Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) to change the administration schedule of BioThrax (Anthrax Vaccine Adsorbed) to a three-dose primary series of intramuscular injections at 0, 1, and 6 months.LONDON, May 17, 2012/PRNewswire-FirstCall/ -- Silence Therapeutics plc, a leading global RNA interference (RNAi) therapeutics company, today announces that top line data from its ongoing Phase I trial of Atu027 [http://silence-therapeutics.com/pipeline ] show that of the 33 patients treated in the first 10 cohorts of the study, 10 patients experienced stable disease after three months.SHANGHAI, May 17, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the first quarter ended March 31, 2012.SUNNYVALE, Calif., May 17, 2012 /PRNewswire/ -- Pharmacyclics, Inc. today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012 in Chicago, IL.BOSTON, May 17, 2012 /PRNewswire/ -- PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it will provide a live webcast of its Investor Day on Thursday, May 31, 2012, from 8:30 a.m. to 12:30 p.m. (EDT).SAN DIEGO, May 17, 2012 /PRNewswire/ -- Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120 (AAV2-neurturin).ISELIN, N.J., May 17, 2012 /PRNewswire/ -- Pharmos Corporation today announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.COLUMBIA, Md.--(BUSINESS WIRE)--May 17, 2012 - Osiris Therapeutics Inc. announced today it has received market authorization from Health Canada to market its stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.SAN DIEGO, May 17, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure.WOODCLIFF LAKE, N.J., May 17, 2012 /PRNewswire/ -- Eisai announced today that 15 abstracts highlighting new study results will be presented during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from June 1 to June 5, 2012.LEXINGTON, Mass.--(BUSINESS WIRE)--May 17, 2012 - Synta Pharmaceuticals Corp. today announced scheduled presentations at the 2012 American Society for Clinical Oncology (ASCO) Annual Meeting June 1-5 at the McCormick Place in Chicago.MALVERN, Pa. and MAHWAH, N.J., May 17, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. and FCB I LLC ("FCB") today announced that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent No. 8,178,518 covering, among other things, Testim 1% testosterone gel, marketed by Auxilium under license from FCB.JERUSALEM--(BUSINESS WIRE)--May 17, 2012 - Teva Pharmaceutical Industries Ltd. announced today that its Board of Directors has unanimously voted to re-elect Dr. Phillip Frost as Chairman of the Board for a term of three years. -
17 May ' 13:21
WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--May 17, 2012 - Biogen Idec and Elan Corporation, plc today announced that the New England Journal of Medicine published research from the companies' global risk management program that updates the risk of TYSABRI (natalizumab)-associated progressive multifocal leukoencephalopathy (PML), an infrequent but serious brain infection that usually leads to death or severe disability, in people with multiple sclerosis (MS).Basel, May 17, 2012 - Results from the pivotal Phase III GLOW2 study demonstrated that once-daily (QD) 50 mcg NVA237 (glycopyrronium bromide) was superior to placebo in improving lung function, symptom relief and quality of life, and reducing exacerbations over a one-year period.ROCKVILLE, Maryland, May 17, 2012 (AP) -- Human Genome Sciences says its board has adopted a "poison pill" shareholder rights plan to ward off unsolicited takeover bids for the biotech drug maker. British pharmaceutical giant GlaxoSmithKline has made an unsolicited takeover bid worth nearly $2.6 billion.DUBLIN--(BUSINESS WIRE)--May 17, 2012 - Alkermes plc today reported financial results for its fourth quarter and fiscal year ended March 31, 2012, and provided financial expectations for its fiscal year 2013, which will be the first full fiscal year of the combined company, Alkermes plc (Alkermes), following the completion of the merger of Alkermes, Inc. with Elan Drug Technologies (EDT) on Sept. 16, 2011.HENDERSON, Nev.--(BUSINESS WIRE)--May 17, 2012 - Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL).SAN DIEGO and JERUSALEM, May 17, 2012 /PRNewswire/ -- Ambit Biosciences and Teva Pharmaceutical Industries Limited today announced the clearance of an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for CEP-32496, a novel BRAF (V600E) kinase inhibitor.ATLANTA--(BUSINESS WIRE)--May 17, 2012 - Dodge Communications, an integrated communications agency serving the healthcare industry, today announced it has been named one of “Atlanta's Best and Brightest Companies to Work For.”WASHINGTON, May 17, 2012 /PRNewswire-USNewswire/ -- Despite increasing budget pressures, countries around the world are making substantial investments in pro-innovation policies and programs to lure the biopharmaceutical research sector away from the U.S., finds a new study released by Battelle Technology Partnership Practice.PITTSBURGH, May 17, 2012 /PRNewswire/ -- Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clopidogrel Tablets USP, 75 mg and 300 mg.WASHINGTON, May 17, 2012 /PRNewswire-USNewswire/ -- The Pharmaceutical Industry Labor-Management Association (PILMA) today called on members of the Senate to support the swift and streamlined process for the reauthorization of the Prescription Drug User Fee Act (PDUFA).HUNTINGTON, W. Va.--(BUSINESS WIRE)--May 17, 2012 - Vandalia Research, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,163,489, covering Vandalia's process for large-scale DNA production using polymerase chain reaction (PCR).HOUSTON--(BUSINESS WIRE)--May 17, 2012 - Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the quarter ended March 31, 2012.TAMPA, Florida, May 17, 2012/PRNewswire-FirstCall/ -- The National Council for Prescription Drug Programs [http://www.ncpdp.org ] (NCPDP), a not-for-profit standards organization with more than 1,500 members throughout the pharmacy services industry, awarded Kay Morgan, Senior Vice President of Drug Products and Industry Standards Research and Compliance for Elsevier / Gold Standard [http://www.goldstandard.com ], with its highest honor, The TIME Award, last week at its annual conference in Phoenix.BOSTON and HONG KONG, May 17, 2012 /PRNewswire/ -- Ventac Partners and the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (GIBH) today announced the creation of CASiGEN Pharma Ltd. (CASiGEN) to bring new treatments for diabetes and other metabolic disorders to the global market.TOKYO, May 17, 2012/PRNewswire-FirstCall/ -- Sosei Group Corporation confirms the information released today by Novartis that results from the pivotal Phase III GLOW2 study demonstrated that once-daily (QD) 50 mcg NVA237 (glycopyrronium bromide) was superior to placebo in improving lung function, symptom relief and quality of life, and reducing exacerbations over a one-year period.RARITAN, N.J., May 17, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy (DPN).BATON ROUGE, La., May 17, 2012 /PRNewswire/ -- Esperance Pharmaceuticals today announced that it has begun enrollment of a Phase 2, randomized, multi-center trial of EP-100 in combination with paclitaxel for the potential treatment of advanced ovarian cancer. EP-100 is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.BALTIMORE, May 17, 2012 /PRNewswire/ -- Ameritox (SM), the nation's leader in pain medication monitoring, announced today the presentation of a peer-reviewed scientific poster titled "Patterns of Drug Use in the Older Chronic Pain Population" at the American Pain Society Annual Meeting.ST. LOUIS, May 17, 2012 /PRNewswire/ -- Sigma-Aldrich Corporation will be presenting at the following investor conferences in June:DALLAS--(BUSINESS WIRE)--May 17, 2012 - Susan G. Komen for the Cure's 2012 research program takes aim at early and late stage breast disease while seeking answers in early detection, cancer prevention, and socioeconomic issues that often make breast cancer outcomes worse in minority and medically under-served women.LIUZHOU CITY, China, May 17, 2012 /PRNewswire-Asia/ -- China BCT Pharmacy Group, Inc., a leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceutical products in Guangxi Province, China, today announced results for the first quarter ending March 31, 2012.YAVNE, Israel--(BUSINESS WIRE)--May 17, 2012 - Avraham Pharmaceuticals Ltd. announced today the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of ladostigil in patients diagnosed with mild cognitive impairment (MCI). This 36-month, multi-centre, randomized, double-blind, placebo-controlled trial will include at least 200 patients in 16 centers in Europe and Israel.FORT LEE, N.J.--(BUSINESS WIRE)--May 17, 2012 - MMM Healthcare, Inc. (MMM), a subsidiary of Aveta Inc., one of the nation's largest managed care providers, was the recipient of two awards last week at the Dorland Case In Point Platinum Awards, held in Washington, D.C.HARBIN, China, May 17, 2012 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines in China, today announced that the Company recently attended and exhibited its anti-depressant products at the 67th PHARMCHINA fair ("the Fair") recently held in Hefei, China.DUBLIN--(BUSINESS WIRE)--May 17, 2012 - Sigmoid Pharma Ltd. (Sigmoid), a privately-owned, specialty pharmaceutical and drug delivery company registered in Ireland, today provides an update on significant progress in 2011 and 2012.WORCESTER, Mass. and TORONTO, May 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation is pleased to announce today that new members have joined the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc. for the company's AE37 breast cancer vaccine.RYE, N.Y.--(BUSINESS WIRE)--May 17, 2012 - The eHealthcare Leadership Awards program, which drew nearly 1,200 entries last year, recognizes the best websites and digital communications of healthcare organizations, online companies, pharmaceutical/medical equipment firms, corporate suppliers, and business improvement initiatives.SAN DIEGO, May 17, 2012 /PRNewswire/ -- The Millennium Research Institute (MRI), a nonprofit national research center formed in 2010, and the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego (UCSD) announced today five scientific articles co-authored by UCSD doctoral pharmacy students have been accepted by the Journal of Analytical Toxicology (JAT).MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--May 17, 2012 - Medgenics, Inc., developer of the novel Biopump technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced receipt of clearance from the U.S. Food and Drug Administration (“FDA” or the “Agency”) to proceed with a Phase IIb clinical trial of EPODURE for the treatment of anemia in patients undergoing renal dialysis.PALO ALTO, Calif., May 17, 2012 /PRNewswire/ -- Ruga Corporation, a privately held oncology company focused on the discovery and development of personalized therapeutics targeting tumor-selective adaptive responses, announced today that as part of its drug adaptation inhibitor program the company has acquired a novel RAF Kinase program to overcome the paradoxical activation of the MAPK pathway in tumors and has appointed Jean-Michel Vernier, Ph.D., as Head of Medicinal Chemistry and David Matthews, Ph.D., as a scientific advisory board member.LOS ANGELES--(BUSINESS WIRE)--May 17, 2012 - KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that it has publicly filed its registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.SANTA CLARA, Calif. & GLOSTRUP, Denmark--(BUSINESS WIRE)--May 17, 2012 - Agilent Technologies Inc. (NYSE:A) and EQT, the Sweden-based private equity group, today announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent's history.AUSTIN, Texas--(BUSINESS WIRE)--May 17, 2012 - The childhood cancer research computing cluster created and donated by Dell for the Translational Genomics Research Institute (TGen) is ready to support the world's first precision medicine clinical trial for pediatric cancer.PARIS, May 17, 2012 /PRNewswire/ -- OrbusNeich today announced that two subgroup analyses from the REMEDEE trial assessing vascular healing of the company's Combo Dual Therapy Stent versus the TAXUS paclitaxel-eluting stent demonstrate an early advantage with the Combo Stent.MALVERN, Pa., May 17, 2012 /PRNewswire/ -- Egalet Ltd., a privately held specialty pharmaceutical company focused on developing safe, effective and abuse-deterrent medications, announced today Bob Radie, president and chief executive officer (CEO), will present at the Life Sciences Europe conference on May 23 organized by the International Venture Club.WALTHAM, Mass.--(BUSINESS WIRE)--May 17, 2012 - PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, announced today that it will be presenting innovative mass spectrometry solutions that reduce analysis time from minutes to seconds by eliminating sample preparation steps. -
17 May ' 03:23
May 17, 2012NEW YORK, May 16, 2012 (AP) -- GlaxoSmithKline PLC has closed on a deal that boosts its interest in biotechnology company Theravance Inc. by 10 million shares.PHILADELPHIA, May 16, 2012 (PHILADELPHIA INQUIRER) - May 16--Johnson & Johnson’s courtroom fights over Risperdal resume in Philadelphia on Wednesday, when Commonwealth Court judges are scheduled to hear an appeal of decisions to dismiss Pennsylvania’s 2008 lawsuit that alleged the company fraudulently profited from sales of the antipsychotic drug through the Medicaid program.DEERFIELD, Ill.--(BUSINESS WIRE)--May 16, 2012 - Baxter International Inc. today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with hemophilia A (congenital factor VIII deficiency) in China by the State Food and Drug Administration (SFDA).BOULDER, Colo.--(BUSINESS WIRE)--May 16, 2012 - Array BioPharma Inc. today announced oral presentations on its two MEK inhibitors, selumetinib (AZD6244) and MEK162 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, which will held June 1-5, 2012 at McCormick Place in Chicago, Illinois.SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc., is expanding its respiratory franchise by focusing on two innovative, comprehensive treatment alternatives for patients with asthma.CLEVELAND, May 16, 2012 /PRNewswire/ -- DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced its attendance at the 4th Annual China Meeting: Collaboration and Innovation in China.ANN ARBOR, Mich., May 16, 2012 /PRNewswire/ -- Rubicon Genomics, Inc., a leader in the development and commercialization of sample-specific pre-analytical processes to improve the performance and capabilities of DNA and RNA analytical platforms for research and clinical testing, today announced the launch of the first product in its innovative ThruPLEX family of sample preparation kits designed and optimized for next generation sequencing (NGS).MONMOUTH JUNCTION, N.J., May 16, 2012 /PRNewswire/ -- Insmed Incorporated, a biopharmaceutical company, today announced the appointments of Donald J. Hayden, Jr. as Executive Chairman of the Company's Board of Directors, and Randall Whitcomb, M.D. as the Lead Independent Director, effective immediately.WEIFANG, China, May 16, 2012 /PRNewswire-Asia/ -- Shengtai Pharmaceutical, Inc., a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today reported financial results for the third quarter of fiscal 2012 ended March 31, 2012.WOONSOCKET, R.I., May 16, 2012 /PRNewswire/ -- MultiCell Technologies, Inc. is pleased to announce representatives from the Company will present preclinical research findings for MCT-465 and MCT-485 at CIMT 2012 (http://meeting.cimt.eu), Europe's largest meeting dedicated to cancer immunotherapy research and development.SAN DIEGO, May 16, 2012 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a pharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today positive results from a Phase 2b study of EP-101 in patients with chronic obstructive pulmonary disease (COPD), a progressive disease comprising chronic bronchitis and emphysema caused largely by smoking.WAYNE, N.J., May 16, 2012 /PRNewswire/ -- Bayer HealthCare announced today that data on Nexavar (sorafenib) tablets and several of its investigational oncology compounds will be presented in a scientific forum at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, in Chicago, IL.SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. today announced the upcoming presentations of data highlighting Nexavar (sorafenib) tablets, Kyprolis (proposed trademark for carfilzomib) and regorafenib, a Bayer-owned compound for which Onyx will receive a royalty on global net sales.SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 16, 2012 - Exelixis, Inc. reiterated its slate of activities in conjunction with the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 1-5, 2012, in Chicago, Illinois.WOONSOCKET, R.I., May 16, 2012 /PRNewswire/ -- CVS Caremark today released its annual Insights Report, which reviews drug trend and highlights key issues in pharmacy care. In 2011, the drug trend for the company's pharmacy benefit management (PBM) employer clients (2.1 percent) and health plan clients (2.2 percent) represented the company's lowest recorded trend for the past seven years.LEXINGTON, Mass.--(BUSINESS WIRE)--May 16, 2012 - Pulmatrix, a biotechnology company developing breakthrough therapies for respiratory diseases, today announced that six posters on its iCALM™ and iSPERSE™ inhaled drug platforms have been selected for presentation at the American Thoracic Society (ATS) 2012 International Conference taking place May 18-23, 2012, in San Francisco, CA.EXTON, Pa.--(BUSINESS WIRE)--May 16, 2012 - Fibrocell Science, Inc. announced today that it has signed an exclusive license agreement with The Regents of the University of California, under which it acquired the rights to commercially apply discoveries resulting from the scientific collaboration between the University of California, Los Angeles (UCLA) and Fibrocell Science, Inc.BALTIMORE, May 16, 2012 /PRNewswire/ -- In an effort to voice concern on biosimilars pathways for patients with primary immunodeficiency diseases (PIDD), the Immune Deficiency Foundation (IDF) offered oral testimony at last week's U.S. Food and Drug Administration (FDA) public hearing on draft guidance of biosimilars products.BLUE BELL, Pa., May 16, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. announced today that its SynCon avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial - a distinct clinical achievement on Inovio's path to develop universal influenza vaccines.CARLSBAD, Calif.--(BUSINESS WIRE)--May 16, 2012 - International Stem Cell Corporation (www.internationalstemcell.com) today announced financial results for the three months ended March 31, 2012.SUNNYVALE, Calif. & PARIS--(BUSINESS WIRE)--May 16, 2012 - Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, today announced outstanding six-month clinical, IVUS (Intravascular Ultrasound), OCT (Optical Coherence Tomography), and angiographic data for its 15-patient First-In-Man clinical study of the fully bioresorbable drug-eluting scaffold, the DESolve Bioresorbable Coronary Scaffold System at a late-breaking trial session of EuroPCR in Paris.ALACHUA, Fla.--(BUSINESS WIRE)--May 16, 2012 - Florida Biologix, a full-service biopharmaceutical development and contract manufacturing organization, provided cGMP manufacturing services to National Taiwan University Hospital under a contract signed in March 2008.COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--May 16, 2012 - Cannabis Science, Inc. a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to provide the latest photos and information on patient three's progress.GLEN ALLEN, Va., May 16, 2012 /PRNewswire/ -- Star Scientific, Inc. announced that the U.S. Patent and Trademark Office issued a Notice of Allowance on May 11, 2012 to Rock Creek Pharmaceuticals, Inc., its wholly owned subsidiary, in Application No. 12/729,346, covering an improved method for the synthetic preparation of anatabine.NEW YORK, May 16, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced it has filed three new patent applications with the United States Patent and Trademark Office (USPTO), which expand the Company's immunotherapy pipeline.CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2012 - Scientia Advisors, a leading management consulting firm specializing in growth strategies for companies in healthcare, life sciences, biotechnology, and health and wellness, today announced that Patrick Terry, Principal, Scientia Advisors, will present at the Genome-wide Partnering and Deal-making Conference, held May 29-31, in Boston.PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--May 16, 2012 - STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only Self-Apposing Stent to treat Acute Myocardial Infarction (AMI), announced today the definite results on the 1,000-patient APPOSITION III clinical study at one month after treatment of a severe heart attack.CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2012 - InVivo Therapeutics Holdings Corp., today announced that the Company's Chief Science Officer, Edward Wirth III, MD, PhD will be presenting at the Interdependence 2012 show currently being held in Vancouver through May 17th, 2012.NOKOMIS, Fla.--(BUSINESS WIRE)--May 16, 2012 - Rainbow Biosciences, the biotechnology subsidiary of Rainbow Coral Corp., announced today that the company is currently discussing a potential joint venture with emerging biotech innovator Amarantus BioSciences.BURLINGTON, Mass.--(BUSINESS WIRE)--May 16, 2012 - As awareness activities take place today across the globe in recognition of Hereditary Angioedema (HAE) Day –– Dyax Corp. has announced a donation of $25,000 to the United States Hereditary Angioedema Association (HAEA) – the largest HAE patient group in the world.SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 16, 2012 - Genentech, a member of the Roche Group, today announced that the company will present important new data from studies of several of its cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1 to 5, 2012, in Chicago.AUSTIN, Texas, May 16, 2012 /PRNewswire/ -- Respira Therapeutics, Inc. (http://www.respiratherapeutics.com), developer of a breakthrough, excipient-free, high efficiency, dry powder inhaler (DPI) drug delivery technology for the treatment of respiratory and systemic diseases, announced today that Armando Anido, former President & CEO of Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), was elected to the Respira Therapeutics, Inc. board of directorsLONDON--(BUSINESS WIRE)--May 16, 2012 - Leading pharmaceuticals company Pfizer outlined its vision for Systems-based Pharmaceutics, a revolutionary model-based approach linking drug process and product engineering to product quality and performance in the human body, at the recent Advanced Process Modelling Forum in London.WALTHAM, Mass.--(BUSINESS WIRE)--May 16, 2012 - ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that there will be four presentations at the upcoming 2012 American College of Clinical Oncology (ASCO) Annual Meeting on compounds that utilize the Company's Targeted Antibody Payload (TAP) technology.PARIS, May 16, 2012/PRNewswire/ -- The SIVAC (Supporting Independent Immunization and Vaccine Advisory Committees) Initiative recently supported the establishment of National Immunization Technical Advisory Groups (NITAGs) in Kazakhstan and Kyrgyzstan.LOS ANGELES, May 16, 2012 /PRNewswire-USNewswire/ -- International Medical Corps will immediately scale up its support to the government of Chad in polio eradication activities through a grant from the Bill & Melinda Gates Foundation.ATLANTA--(BUSINESS WIRE)--May 16, 2012 - Mary L. Yost, President of THE SAGE GROUP LLC, announced that 2012 marked the company's 10th anniversary.BENTONVILLE, Ark., May 16, 2012 /PRNewswire/ -- Walmart announced today that it will be among the first retailers to offer Clopidogrel, the generic version of Plavix. -
15 May ' 21:36
May 16, 2012PRINCETON, N.J. & BEIJING, China--(BUSINESS WIRE)--May 15, 2012 -Bristol-Myers Squibb Company and Tsinghua University of Beijing, China, today announced the formation of a multi-year strategic partnership. -
15 May ' 13:02
May 15, 2012PHOENIX, May 15, 2012 /PRNewswire/ -- In collaboration with the National Institutes of Health (NIH), Banner Alzheimer's Institute (BAI), University of Antioquia in Colombia and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announce the first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer's disease because of their genetic history.NEW YORK--(BUSINESS WIRE)--May 15, 2012 - Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the company's biologics manufacturing facility in Devens, Massachusetts for commercial production of ORENCIA (abatacept).DARMSTADT, Germany, May 15, 2012 – Merck announced today details of its planned cost efficiencies for Merck Serono and introduced mid-term financial targets at its Capital Markets Day in Darmstadt. These details are part of the Group’s previously announced plan to transform the company through a comprehensive efficiency program.BAGNEUX, France--(BUSINESS WIRE)--May 15, 2012 - DBV Technologies, creator of Viaskin, a new standard in the treatment of allergy, announced today its first quarter topline and its intense scientific activity and clinical data disclosure schedule for the coming weeks.RESTON, Va.--(BUSINESS WIRE)--May 15, 2012 - Aptiv Solutions, a biopharmaceutical and medical device development services company, and leader in adaptive clinical trial design, simulation and execution, announced today the appointment of Luis T. Gutierrez, Jr. as Executive Vice President and Chief Commercial Officer. In this role, he will oversee the global Business Development, Proposal Development, Marketing and Brand Management functions at Aptiv Solutions.STOCKHOLM--(BUSINESS WIRE)--May 15, 2012 - Medivir AB, a research-based specialty pharmaceutical company focused on infectious diseases, announced today that it has appointed Henric Juserius to be the new head of the company's commercial activities.PALO ALTO, Calif., May 15, 2012 /PRNewswire/ -- Telik, Inc. today announced two publications in the Journal of Hematology & Oncology. The first is "Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)," Raza, A., et al., Journal of Hematology & Oncology 2012, 5:18 doi:10.1186/1756-8722-5-18; 30 April 2012. The publication may be found at http://www.jhoonline.org/content/pdf/1756-8722-5-18.pdf.CALGARY, May 15, 2012 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc., will present a corporate overview of the Company at the Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday, May 15 th , 2012 at 8:40 a.m. PT .BEIJING, May 15, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012.ROCKVILLE, Md., May 15, 2012 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2012.HALLE, Germany--(BUSINESS WIRE)--May 15, 2012 - Scil Proteins GmbH, a private biotech company specializing in the research, development and production of recombinant proteins, today announced that it has signed a collaboration agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan), for the joint discovery and development of new Affilin therapeutics to treat various diseases.EMERYVILLE, Calif., May 15, 2012 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has held an End-of-Phase 2 meeting with the FDA to discuss the proposed safety and efficacy studies to be conducted for the registration of Arimenda (memantine HCl extended release and donepezil HCl) capsules.XIANYANG, China, May 15, 2012 /PRNewswire-Asia/ -- Biostar Pharmaceuticals, Inc., a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the first quarter ended March 31, 2012.CAMBRIDGE, England--(BUSINESS WIRE)--May 15, 2012 - Lab21 Limited, the Cambridge, UK-based specialist in personalised medicine has secured new patents in Europe and the USA relating to Hepatitis C (HCV) drug resistance as it continues to expand its intellectual property portfolio in infectious disease testing.EWING, N.J.--(BUSINESS WIRE)--May 15, 2012 - Antares Pharma, Inc. today announced the appointment of LeRoux Jooste to the position of Senior Vice President of Pharmaceutical Sales and Marketing.JERUSALEM--(BUSINESS WIRE)--May 15, 2012 - Gamida Cell announced today that it has closed an internal E financing round of $10 million. All major shareholders participated.EAST RUTHERFORD, N.J., May 15, 2012 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased to announce that Steve Klosk, President and Chief Executive Officer, will make a presentation on the Company at the Jefferies 2012 Global Healthcare Conference on June 4, 2012 at 9:30 AM EDT in New York City.HAMILTON, N.J., May 15, 2012 /PRNewswire/ -- Today, leading events organizer UBM Live announced strong booking levels for Informex 20I3, North America's leading networking event for buyers and sellers of high value chemistry. 248 exhibitors have already confirmed participation at the flagship show which takes place from February 19th to 22nd of 2013 at the Anaheim Convention Center, Anaheim, CA.BRANFORD, Connecticut and SHENZHEN, China, May 15, 2012/PRNewswire/ -- BGI, one of the world's largest genomics organizations, announced today that a new Roche GS FLX+ System has been successfully installed at its facility in Shenzhen, China.ANN ARBOR, Mich., May 15, 2012 /PRNewswire/ -- Synthetic Biologics, Inc., a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, today reported financial results for the three months ended March 31, 2012 and summarized operational highlights.CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2012 - Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that the company will be added to the NASDAQ Biotechnology Index® (NBI). The semi-annual re-ranking of the index will become effective prior to market open on Monday, May 21, 2012.PARIS--(BUSINESS WIRE)--May 15, 2012 - As EuroPCR 2012 gets under way today, Medtronic, Inc. (NYSE: MDT) announced that the Resolute Integrity Coronary Stent System has received European regulatory approval for several new indications, making it the drug-eluting stent (DES) with the broadest range of approved indications in Europe.PRINCETON, N.J.--(BUSINESS WIRE)--May 15, 2012 - Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has retired approximately $4.5 million in aggregate convertible debt due on May 12, 2012, October 31, 2012, and January 9, 2013.THE WOODLANDS, Texas--(BUSINESS WIRE)--May 15, 2012 - Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2012.A conference call will be held for the holders of 11.375% Senior Subordinated Notes on Thursday, May 24th at 1:30pm Eastern Time to discuss the results. All bondholders should contact Renee Verrastro (rverrastro@medimedia.com) to obtain access to the financial report and conference call dial-in details.BUENA, N.J.--(BUSINESS WIRE)--May 15, 2012 - IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the first quarter ended March 31, 2012.IRVINE, Calif.--(BUSINESS WIRE)--May 15, 2012 - Cortex Pharmaceuticals, Inc. (OTCBB (CORX)) reported a net loss of approximately $934,000, or $0.01 per share, for the quarter ended March 31, 2012, compared with a net loss of approximately $1,556,000, or $0.02 per share, for the corresponding prior year period, with the difference including expenses incurred in the prior year period to reacquire the respiratory depression project that Biovail purchased from the Company in March 2010.CARLSBAD, Calif.--(BUSINESS WIRE)--May 15, 2012 - International Stem Cell Corporation (OTCBB: ISCO) (www.internationalstemcell.com) today announced that several of its leading scientists will present experimental results from three of ISCO's pre-clinical therapeutic programs.JERUSALEM--(BUSINESS WIRE)--May 15, 2012 - BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today reported its results for the quarter ended March 31, 2012.MADISON, Wis., May 15, 2012 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the first cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.RICHMOND, Va.--(BUSINESS WIRE)--May 15, 2012 - MeadWestvaco Corporation (NYSE: MWV), a global leader in packaging and packaging solutions, will present at Pharmapack North America's inaugural conference at the Pennsylvania Convention Center in Philadelphia, May 22 – 23, 2012.LOS ANGELES--(BUSINESS WIRE)--May 15, 2012 - CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced a reverse split of its common stock at a ratio of 1-for-7. CytRx's common stock will begin trading on NASDAQ on a split-adjusted basis when the market opens on May 16, 2012. The Company's Board of Directors unanimously approved the reverse split following stockholder approval, which was announced at the Company's 2012 Annual Meeting of Stockholders held May 14, 2012.DUBLIN, Ohio, May 15, 2012 /PRNewswire/ -- Cardinal Health today said it had agreed to a settlement with the Drug Enforcement Agency (DEA) that allows the company to bring resolution to ongoing litigation. Cardinal Health agreed to a two-year suspension of its Lakeland, Fla., distribution center's DEA registration to ship controlled medicines from this facility and to improve certain anti-diversion procedures. The Lakeland distribution center will remain open, and all other operations at the facility will continue. The DEA also confirmed it is planning no further administrative actions at other Cardinal Health facilities.EMERYVILLE, Calif.--(BUSINESS WIRE)--May 15, 2012 - KineMed Inc. (www.kinemed.com) announced today that David Fineman, KineMed's President & CEO, will be a panelist in the session titled “Movement Disorders: Parkinson's, Huntington's, and ALS” being held at the 7th annual Neurotech Investing & Partnering Conference at 3:30 PM EST May 21st at the Intercontinental Hotel Boston.BRIDGEWATER, N.J.--(BUSINESS WIRE)--May 15, 2012 - Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today reported financial results for the third quarter of fiscal year 2012 which ended on March 31, 2012.NEWTON, Mass.--(BUSINESS WIRE)--May 15, 2012 - Galectin Therapeutics (NASDAQ: GALT) (“the Company”), the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma. The trial, being conducted in collaboration with the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR), is evaluating Galectin Therapeutics' carbohydrate-based galectin inhibitor compound, GM-CT-01, in combination with a Ludwig Institute peptide vaccine.SALT LAKE CITY--(BUSINESS WIRE)--May 15, 2012 - Alliance Health Networks, the leading social networking company serving consumers and the healthcare industry, today announced that it has acquired Medify, a leading provider of data-driven treatment information, to offer patients and caregivers the industry's most comprehensive social engagement platform. -
14 May ' 17:59
COPENHAGEN, May 14, 2012 - H. Lundbeck A/S (Lundbeck) today announced positive top-line results from three recently completed phase III clinical studies of Lu AA21004, an investigational drug for the treatment of adults with major depressive disorder (MDD) using dosages from 10 to 20mg.SILVER SPRING, Md., May 14 2012-- The U.S. Food and Drug Administration (FDA) has completed its evaluation of a report of a patient who died after the first dose of multiple sclerosis drug Gilenya (fingolimod).SAN MATEO, Calif.--(BUSINESS WIRE)--May 14, 2012 - Maxygen, Inc. (Nasdaq:MAXY), a biopharmaceutical company, today announced that it will receive a $30.0 million payment from Bayer HealthCare LLC in connection with Bayer's continued clinical development of a recombinant factor VIIa product candidate for the treatment of hemophilia.PARSIPPANY, N.J., May 14, 2012 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), today reported financial and operational results for the first quarter ended March 31, 2012. Summary financial and operating highlights include:POINT RICHMOND, Calif., May 14, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three months ended March 31, 2012.SAN DIEGO, May 14, 2012 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that it will be added to the NASDAQ Biotechnology Index® (Nasdaq: NBI) effective Monday, May 21, 2012.LEXINGTON, Mass.--(BUSINESS WIRE)--May 14, 2012 - Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the results from the Phase 2 studies of CB-5945 (formerly ADL5945) in patients with chronic non-cancer pain and opioid-induced constipation (OIC) will be presented at the 31st Annual Scientific Meeting of the American Pain Society taking place May 16 to 19, 2012, in Honolulu and during Digestive Disease Week 2012 taking place May 19 to 22, 2012, in San Diego.EMERYVILLE, Calif. & NEW YORK--(BUSINESS WIRE)--May 14, 2012 - KineMed, Inc. (www.kinemed.com) and CHDI Foundation, Inc. announced today a collaboration to use KineMed's isotopic labeling and dynamic proteomics platform to investigate the turnover rates of huntingtin protein, a mutant form of which plays a central role in the pathogenesis of Huntington's disease (HD).JERSEY CITY, N.J., May 14, 2012, 2012 /PRNewswire/ -- S1 Biopharma, an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions, today announced its foray into male sexual health with S1P-205, the first and only drug in development for male HSDD.MONTREAL, May 14, 2012/PRNewswire/ -- Piramal Healthcare Bio-Orthopaedics, a division of Piramal Healthcare Limited [NSE: PIRHEALTH, BSE: 500302], today announced that positive data from their pivotal (Phase III) clinical trial is being presented in 3 podium presentations as well as during an Industry Symposium at the 10th World Congress of the International Cartilage Repair Society (ICRS), May 12 to 15, in Montreal, Quebec, Canada.BEIJING, May 14, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, has appointed Mr. Danny Chung as Chief Financial Officer, effective immediately. Ms. Nan Wang, who has served as interim Chief Financial Officer since August 2011, will continue as the Company's Vice President.NEW YORK--(BUSINESS WIRE)--May 14, 2012 - New data will be presented on targeted cancer treatments from the Pfizer Oncology portfolio across three key therapeutic categories, including tumors of the kidney, lung and hematologic malignancies, at the Annual Meeting of the American Society of Clinical Oncology in Chicago, IL, from June 1-5. Approximately 100 abstracts featuring Pfizer's cancer treatments and investigational compounds across 20 cancer types will be presented during the meeting.CHICAGO--(BUSINESS WIRE)--May 14, 2012 - ClearTrial (http://www.cleartrial.com) announced today that the company has released a new web video, “Best Practices to Improve Operational Efficiency in Clinical Development,” featuring Gartner Research Vice President Steven Lefebure and ClearTrial CEO Mike Soenen. The complimentary video, available for viewing at http://www.accelacomm.com/acc/cleartrial/0/50147716/, offers life sciences companies insights into how their peers are improving efficiency and productivity in their R&D operations.CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--May 14, 2012 - Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will present linaclotide-related data in one oral presentation and 16 poster presentations during Digestive Disease Week (DDW) 2012 being held in San Diego, May 19 through May 22, 2012. Linaclotide is an investigational guanylate cyclase type-C agonist (GCCA) for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation.PRINCETON, N.J.--(BUSINESS WIRE)--May 14, 2012 - Bristol-Myers Squibb Company (NYSE: BMY) today announced that the company will present 18 abstracts on ORENCIA (abatacept) at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Berlin, June 6-9.CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 14, 2012 - Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today reported financial results for the quarter ended March 31, 2012 and also commented on certain corporate accomplishments and plans.VANCOUVER, May 14, 2012 /PRNewswire/ - Allon Therapeutics Inc. (TSX: NPC) announced today that a presentation given May 12 at the prestigious 12th International Stockholm / Springfield Symposium on Advances in Alzheimer Therapy featured new research with Allon's lead product candidate, davunetide , showing a prevention of neuronal cell death. This research was recently published in the International Journal of Alzheimer's Disease.BASEL, Switzerland & LONDON--(BUSINESS WIRE)--May 14, 2012 - S.L.A. Pharma AG has announced clinically and statistically significant top-line data from their Phase 2 double blind randomised placebo controlled study. The study was designed to evaluate the safety and efficacy of 4 doses of Nalcol™, a novel oral formulation of naloxone (2.5, 5, 10, and 20 mg), in treating opioid induced constipation (OIC) in patients with persistent non-cancer pain.INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- BioStorage Technologies, a global provider of comprehensive sample management solutions for the bioscience industry, including storage, cold chain logistics and virtual sample intelligence, will host its European Global Sample Management Benchmarking Symposium on 22 May 2012 in Brussels, Belgium from 16:00 – 18:00 (GMT +1).INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 – 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA® (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer. Lilly presented progression-free survival data from PARAMOUNT at the 2011 ASCO meeting.SAN DIEGO, May 14, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the completion of its previously announced rights offering to stockholders, which expired on Friday, May 11, 2012.CAMBRIDGE, Mass. and SCHLIEREN-ZURICH, Switzerland, May 14, 2012 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today that it has entered into collaboration with Neurotune to investigate a potential treatment for ALS (aka Motor Neuron or Lou Gehrig's disease).INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from several molecules that make up its clinical oncology pipeline during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 1 – 5, 2012.NEW YORK--(BUSINESS WIRE)--May 14, 2012 - TransPerfect, a leading provider of e-clinical technologies to the life sciences industry, today announced that INC Research, a therapeutically focused clinical research organization (CRO), has selected Trial Interactive as its global electronic Trial Master File (eTMF) solution. Trial Interactive is a secure, web-based platform that reduces the redundancies inherent in paper-based TMF management.OR AKIVA, Israel and PRINCETON, New Jersey, May 14, 2012, 2012 /PRNewswire/ -- Regentis Biomaterials Ltd., a privately held company focused on developing proprietary hydrogels for tissue regeneration, announced that it has raised $10 million in its latest round of funding from new investors Royal DSM through its venturing subsidiary and from Crossroad Fund, as well as from existing investors Medica Venture Partners, SCPVitalife and the Technion Investment Opportunities Fund.EXTON, Pa.--(BUSINESS WIRE)--May 14, 2012 - Fibrocell Science, Inc. (OTCBB: FCSC) announced today that is has submitted to the U.S. Food & Drug Administration (FDA) the company's Phase II clinical study protocol to evaluate the safety and efficacy of Fibrocell's lead therapy, azficel-T, in improving the range of motion, function and flexibility, in patients with existing restrictive burn scars.SAN CARLOS, Calif.--(BUSINESS WIRE)--May 14, 2012 - Cellerant Therapeutics, Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the publication of a radiation countermeasure study demonstrating that cryopreserved, allogeneic mouse myeloid progenitor cells significantly improved survival in mice irradiated with lethal doses of radiation.ATLANTA--(BUSINESS WIRE)--May 14, 2012 - CDC Software, an enterprise software provider of on-premise and cloud technologies, today announced that Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, plans to implement Ross Enterprise to manage its growth, while helping to improve efficiency, reduce costs, facilitate compliance and mitigate risk.WALTHAM, Mass.--(BUSINESS WIRE)--May 14, 2012 - Affinnova, Inc., the global leader in innovation software and services, announced today that Charu Chaturvedi, Senior Vice President, Affinnova Life Sciences, will make a presentation on “Repositioning for Product Success by Leveraging the Power of Your Brand” and co-present with Gaurav Kapoor, President, Disruptyx at the Pharmaceutical Business Intelligence & Research Group (PBIRG)'s Annual General Meeting. The event will be held May 20-23, 2012 in Chicago, IL.FRESH MEADOWS, N.Y., May 14, 2012, 2012 /PRNewswire/ --Pharmaceutical manufacturers and distributors face new Food and Drug Administration (FDA) mandates requiring reporting on drug product samples distribution using XML, and submitting the report through the FDA gateway.HORSHAM, Pa.--(BUSINESS WIRE)--May 14, 2012 - Acurian, Inc., a leading, full-service provider of global patient enrollment and retention solutions, announced today that the first quarter was a new company record in terms of bookings, revenue, backlog, and new customers signed in a three-month period.CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 14, 2012 - Helicos BioSciences Corporation (OTCQB: HLCS.PK) announced today that it has settled its patent infringement litigation against Pacific Biosciences, Inc.MIAMI--(BUSINESS WIRE)--May 14, 2012 - OPKO Health, Inc. (NYSE:OPK) today announced the receipt of a patent allowance from the U.S. Patent and Trademark Office (USPTO) for the patent application titled “Flow Control in Microfluidic Systems”.LOUISVILLE, Ky.--(BUSINESS WIRE)--May 14, 2012 - PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, today announced that Gregory S. Weishar, Chief Executive Officer, will make a presentation regarding the Company at the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas on Wednesday, May 16, 2012, at 11:20 a.m. Pacific Time.BOSTON, May 14, 2012 /PRNewswire/ -- More than half of all image-related clinical trial query stoppages result from preventable human errors, according to industry research. In response, AG Mednet announces its "Submission Quality & Compliance" module that delivers a new layer of automated quality assurance to reduce submission error rates and bring preventable delays to zero. AG Mednet's technology network supports all organizations in the clinical trial ecosystem: imaging core labs, clinical research organizations, imaging trial sponsors and principal investigators.WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--May 14, 2012 - Cynvenio Biosystems, Inc., a developer of rare cell isolation systems for biomedical research in circulating tumor cells, personalized medicine and the molecular diagnostics of cancer, announced today that Fred Gluck, its co-Founder and Chairman of the Board, will be the recipient of the 2012 South Coast Pioneer Award.PARIS--(BUSINESS WIRE)--May 14, 2012 - Cegedim Relationship Management today announced that Galderma Italy has fully deployed the cloud-based, next generation Customer Relationship Management (CRM) solution, Mobile Intelligence for iPad™ for its specialty commercial team. The integrated solution also includes OneKey™, the most comprehensive healthcare professional (HCP) database, and Xtelligence, which delivers cross-enterprise performance dashboards for invaluable commercial analysis, in order to enhance Galderma Italy's market knowledge and the results of field force initiatives.CRAIGAVON, Northern Ireland--(BUSINESS WIRE)--May 14, 2012 - Almac announced today the acquisition of the new PharmaWorks TF3 high-speed / large-format blister equipment. The addition addresses a growing industry need for outsourced clinical trial services and follows another recent acquisition, the Bosch GKF 702 over-encapsulation machine. Both pieces of equipment will be housed in Almac's North American headquarters in Souderton, PA, reinforcing the company's global capacity by complementing existing equipment currently in the Craigavon, Northern Ireland global headquarters. -
14 May ' 04:51
May 14, 2012Tokyo, Japan, May 11, 2012-- McCann Healthcare Worldwide Japan (MHWWJ, a division of McCann Healthcare Worldwide, McCann Worldgroup and Interpublic Group [NYSE: IPG]) announced today the creation of MDS-CMG, the new Japanese healthcare communications leader in scientific content across all therapeutic areas. This new business entity has been formed through the acquisition of a 51% interest in MDS Co., Ltd. Kazuko Oneda, who has run MDS, will continue as President of MDS-CMG, reporting to Amar Urhekar, President of MHWWJ.FOSTER CITY, Calif.--(BUSINESS WIRE)--May 11, 2012 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 1 in support of approval of the Quad, a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, for the treatment of HIV-1 infection in treatment-naïve adults.SEATTLE, May 11, 2012 (SEATTLE TIMES) - Cell Therapeutics said its cancer drug pixantrone has been approved by the European Commission for treating late-stage, aggressive B-cell non-Hodgkin lymphomas that haven’t responded to other therapies.14 May 2012, Melbourne, Australia: Australian biopharmaceutical company Immuron Limited (ASX: IMC), manufacturer of Travelan, has entered into an agreement with Singaporean company Ziwell Medical (S) Pte Ltd for the distribution of Travelan in Singapore, Malaysia and Brunei.SILVER SPRING, Md., May 14 2012-- On April 30, 2012, FDA granted tentative approval under expedited review provisions of the President's Emergency Plan for AIDS Relief, or PEPFAR, for nevirapine tablets 200 mg.Mont-Saint-Guibert, Belgium, May 14, 2012 – Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, today announces it has treated its first two patients with its innovative treatment based on allogeneic adult liver stem cell technology (HepaStem).Berlin, May 14, 2012 - The biotechnology company MOLOGEN AG has conducted an initial assessment of the phase 2 colorectal cancer study with MGN1703. The assessment of 55 patients showed that the primary endpoint, the prolongation of the median progression-free survival, was achieved.MISSISSAUGA, ON, May 11, 2012 - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology and cancer related products, today reported operational and financial results for its third quarter of fiscal 2012, ended March 31, 2011.SAN DIEGO, May 11, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com) announced today that Health Canada has granted the Company's request for a Pre-New Drug Submission ("Pre-NDS") meeting to obtain regulatory guidance from the agency for MycoVa(TM), the Company's topical treatment for onychomycosis, or nail fungus.Ingelheim, Germany, 20 April 2012 - Highly anticipated results from LUX-Lung 3, the pivotal Phase III lung cancer trial investigating Boehringer Ingelheim's front running oncology investigational compound, the ErbB Family Blocker afatinib, in patients with EGFR mutations, will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012. LUX-Lung 3, which compares afatinib to standard platinum based chemotherapy, is the largest Phase III trial in first-line EGFR mutation positive, advanced, metastatic non-small cell lung cancer (NSCLC) patients(Research Triangle Park, N.C.) Innovative pharmaceutical PR and media relations firm Global Media Strategies (GMS) has published the free informative podcast “How to Do Public Relations” to help small business owners and marketing executives understand how to build and manage an effective communication program.Edmonton, Alberta -May 11, 2012: Isotechnika Pharma Inc.(TSX:ISA) today announced financialresults for the three months ended March 31, 2012.NEWTON, Mass.--(BUSINESS WIRE)--May 11, 2012 - Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for first quarter, ended March 31, 2012. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.DIEPENBEEK, Belgium, May 11, 2012/PRNewswire/ -- Amakem NV, a kinase platform company focusing on ophthalmology, today announces the appointment of Dr. Steve Pakola as Chief Medical Officer and Dr. George Lasezkay to its Board as an Independent Director. Both have exceptional track records in the biotechnology industry and bring a wealth of ophthalmology experience to Amakem.NANJING, China, May 11, 2012 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that the annual general meeting of shareholders (the "Meeting") will be held on Friday, May 25, 2012 at 10 a.m. Beijing time. The meeting will be held at No.699-18, Xuanwu Avenue, Xuanwu District, Nanjing, the People's Republic of China.NEW YORK--(BUSINESS WIRE)--May 11, 2012 - Tonix Pharmaceuticals Holding Corp. (OTCBB: TNXP) (“TONIX” or the “Company”), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system (“CNS”), including fibromyalgia syndrome (“FM”) and post-traumatic stress disorder (“PTSD”), today announced the appointment of Samuel R. Saks, M.D. (age 57) to the Company's Board of Directors. Dr. Saks has more than 25 years of experience developing pharmaceutical products for CNS conditions, including Xyrem® and Concerta®. With this appointment the TONIX Board has eight DirectorsBEIJING, May 11, 2012 /PRNewswire-Asia-FirstCall/ China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, today announced that the Company's Board of Directors (the "Board") has appointed Chairman David (Xiaoying) Gao to the additional position of Chief Executive Officer, effective May 10, 2012. Mr. Gao succeeds Mr. Colin (Chao Ming) Zhao, who will continue to serve as the President of the Company.MALVERN, PA., May 11, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the BofAML 2012 Health Care Conference to be held May 15-17, 2012 at the Encore at the Wynn in Las Vegas. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 11:20 a.m. PT on Wednesday, May 16, 2012.COLUMBIA, Md.--(BUSINESS WIRE)--May 11, 2012 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and commercializing products to treat medical conditions in inflammatory, cardiovascular, orthopedic, and wound healing markets, announced today its results for the first quarter ended March 31, 2012.THE WOODLANDS, Texas--(BUSINESS WIRE)--May 11, 2012 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended March 31, 2012 and provided an update on recent corporate developments.VALLEY FORGE, Pa.--(BUSINESS WIRE)--May 11, 2012 - AmerisourceBergen Corporation (NYSE: ABC) today announced that Tim G. Guttman, 53, has been named Senior Vice President and Chief Financial Officer, effective immediately. Guttman will report to Steven H. Collis, AmerisourceBergen's President and Chief Executive Officer. He had been serving as the Company's Acting Chief Financial Officer since February 13, 2012, and was Vice President and Corporate Controller since joining AmerisourceBergen in 2002.NES-ZIONA, Israel, May 11, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH; TASE: PBTH), today announced the pricing of its previously announced underwritten public offering of 6.5 million shares of its common stock at a price to the public of $5.00 per share.THOUSAND OAKS, Calif., May 11, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that Joseph P. Miletich, M.D., Ph.D., senior vice president of Research and Development at Amgen will testify at the United States (U.S.) Food and Drug Administration (FDA) stakeholder hearing on biosimilars. Miletich will urge members of the FDA panel charged with implementing a pathway for biosimilars to establish approval standards that advance patient safety and promote confidence in biosimilars marketed in the U.S.BOTHELL, Wash.--(BUSINESS WIRE)--May 11, 2012 - Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the first quarter ended March 31, 2012.BOTHELL, Wash.--(BUSINESS WIRE)--May 11, 2012 - Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday, May 15, 2012 at 1:00 p.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics' website at www.seattlegenetics.com in the Investors and News section.CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 11, 2012 - InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), announced today the appointment of Jack Harvey as Senior Director of Manufacturing and Celina Chang as Senior Scientist as the Company ramps up preparations for a human clinical trial and begins to expand its product portfolio to other nervous system conditions.PHILADELPHIA--(BUSINESS WIRE)--May 11, 2012 - Lannett Company, Inc. (NYSE Amex: LCI), a manufacturer of generic pharmaceuticals, today announced the appointment of Paul Taveira to its board of directors, expanding the company's board to eight members.SANTA CLARA, Calif.--(BUSINESS WIRE)--May 11, 2012 - Affymetrix, Inc. (Nasdaq:AFFX) today invited investors and interested parties to hear a live webcast of its Annual Shareholder Meeting at 8:00am PT on Friday, May 11th, 2012. Following the formal business of the meeting, Affymetrix President and Chief Executive Officer Frank Witney will provide an update on the company's strategic direction and operating results.PRINCETON, N.J.--(BUSINESS WIRE)--May 11, 2012 - Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that Barry Wolfenson, the Company's Executive Vice President for Global Marketing and Business Development will present a corporate overview and update at the Bank of America Merrill Lynch 2012 Health Care Conference taking place from Monday, May 14 - Thursday, May 17, 2012 at the Encore at the Wynn in Las Vegas, Nevada. The Company's presentation will take place on Wednesday, May 16, 2012 at 1:00 p.m. local time.HAWTHORNE, N.Y.--(BUSINESS WIRE)--May 11, 2012 - Taro Pharmaceutical Industries Ltd. (NYSE: TARO, “Taro”) announced that its Annual Report for the fiscal year ended December 31, 2011 on Form 20-F, filed with the Securities and Exchange Commission (the “SEC”) on April 5, 2012, is available within the Investor Relations section of Taro's website at www.taro.com. Hard copies of the report may be ordered free of charge by sending requests to Taro Pharmaceuticals U.S.A., Inc., 3 Skyline Drive, Hawthorne, NY 10532, attention: William J. Coote or via email to William.Coote@Taro.com.GREENWOOD VILLAGE, Colo., May 11, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion, Optina and Zertane) announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research (CBER) division of the FDA that took place on May 10th regarding Ampio's lead biologic, Ampion for the chronic treatment (repeat injections) of pain in osteoarthritis (OA) of the knee.ATLANTA, May 11, 2012 /PRNewswire/ -- Older patients with high cholesterol or high blood pressure are at particular risk for unnecessary hospitalizations if they don't follow doctor's orders on taking their medications, according to new research from Express Scripts (NASDAQ: ESRX) presented this week.RAVENSBURG, Germany--(BUSINESS WIRE)--May 11, 2012 - The pharma and biotech industries are increasingly seeking safer and more efficient supply chain processes. To meet these challenges Vetter has invested in a new, state-of-the-art Center for Visual Inspection and Logistics. The new facility offers high-bay warehousing capacity for cool and room-temperature goods employing state-of-the-art technology. The contract development and manufacturing organization (CDMO) is also setting high safety standards for quality control at the location. The 35-million-euro facility will serve as a workplace for up to 400 employees.OSAKA, Japan, May 11, 2012 – Takeda Pharmaceutical Company Limited is implementing the “Transformation into a new Takeda,” guided by its corporate Vision of achieving Growth through Innovation and Culture, in order to realize a new start as a truly global pharmaceutical company.May 11, 2012 (AP) - Shares of Arena Pharmaceuticals Inc. nearly doubled in price in premarket trading Friday, the day after Food and Drug Administration advisers recommended approval for its potential weight-loss drug lorcaserin. -
10 May ' 07:25
May 10, 2012BOSTON, May 10, 2012 (BOSTON HERALD) - A locally waged battle against cystic fibrosis has yielded an experimental drug combination that is giving new hope to families affected by a disease that historically has meant death at an early age.BASEL, Switzerland, May 10, 2012 - Research on Lucentis (ranibizumab) is highlighted in more than 200 abstracts this week at the 2012 Association for Research in Vision and Ophthalmology (ARVO) annual meeting.RARITAN, N.J., May 9, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of Xarelto (rivaroxaban), an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome (ACS).BOUDRY, Switzerland--(BUSINESS WIRE)--May. 10, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from three phase III studies evaluating the use of continuous REVLIMID (lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.ZUG, Switzerland 10 May 2012 - Actavis Group, the international generic pharmaceuticals company, today announced the launch of Atorvastatin, the generic equivalent of Pfizer's Lipitor/Zarator the world's top selling drug.LAVAL, QC, May 10, 2012 /CNW/ - BELLUS Health Inc. today announced a study update and preliminary blinded data on patient demographics and baseline characteristics for the ongoing Phase III trial to confirm the safety and efficacy of Kiacta (eprodisate) in the treatment of AA amyloidosis. Bellus' strategic partner for Kiacta, Celtic Therapeutics, provided the update as part of its participation in the XIII International Symposium on Amyloidosis at the University Medical Center of Groningen in The Netherlands.Costa Mesa, CA – May 9, 2012 – Pacific Communications, the largest healthcare communications agency on the West Coast, is pleased to announce the addition of Account Executive Emily Alford, who is joining the BOTOX® Therapeutic account team. Alford was previously an account executive at 3v07 Advertising in Laguna Beach, Calif. She holds a Bachelor of Science in child and adolescent studies from California State University, Fullerton.Karolinska Development – Interim report January - March, webcast and conference call Tuesday, May 15STOCKHOLM – May 10, 2012. Karolinska Development will publish its interim report for January - March 2012 on Tuesday, May 15, during the day. The company will also host a live webcast and a conference call on the same day at 16.30 CET.QUEBEC CITY, May 10, 2012 /CNW/ - Medicago Inc. (TSX: MDG), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Mike Wanner, Executive Vice President, Operations, will be presenting at the 13th Annual BioEquity Europe Conference. The conference is being held May 15-16, 2012, at the Frankfurt Marriott Hotel in Frankfurt, Germany. Mr. Wanner is scheduled to present on May 16th, 2012, at 11 a.m. Central European Time.On Thursday, May 10, at 11:30 AM Eastern Time (8:30 AM PT), QLT Inc. will hold a conference call to present and discuss the data from the Phase 1b trial of QLT091001 in subjects with Retinitis Pigmentosa (RP) due to RPE65 and LRAT mutations presented earlier that morning at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting.Tokyo, Japan, May 10, 2012 --- Teijin Pharma Limited announced today the launch of febuxostat, a novel drug developed by Teijin Pharma for the treatment of hyperuricemia with gout, in Taiwan. Astellas Pharma Taiwan, Inc., the febuxostat licensee in Taiwan, is marketing the product under the brand name FEBURIC.Vancouver, BC May 9, 2012 — Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR, TSX: TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it will hold a conference call and webcast on Tuesday, May 15, 2012 at 1:30 pm Pacific Time (4:30 pm Eastern Time) to provide a corporate update and report financial and operating results for the first quarter ended March 31, 2012.NEW HAVEN, Conn., May 9, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2012. For the first quarter of 2012, the Company reported a net loss of $9.1 million or $0.13 per share, compared with a net loss of $10.1 million or $0.17 per share for the first quarter of 2011. Cash, cash equivalents and marketable securities as of March 31, 2012 were $70 million.LAKE OSWEGO, Ore., May 10, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, was notified that RXi Pharmaceuticals' common stock is scheduled to commence trading under the symbol "RXII."Groningen, the Netherlands, May 10, 2012 / B3C newswire / - Dutch vaccine development company Mucosis B.V. today announced Phase I clinical data providing proof-of-concept that Mimopath-based mucosal vaccines are safe and well tolerated as well as able to produce balanced immune responses in both circulating blood and the respiratory tract.May 10, 2012. Sophia Antipolis, France. www.nicox.com -NicOx S.A. (NYSE Euronext Paris: COX) today reports financial results for the first three months of 2012 and provides an overview of its activities.Regensburg, Germany, May 10, 2012 / B3C newswire / - The biopharmaceutical company Antisense Pharma announces the appointment of Dr. Philippe Calais as CEO. The native-born Frenchman has more than two decades of international experience in executive positions in biotech and pharmaceutical companies – including Hofmann La-Roche and ICI Pharmaceuticals – and has successfully guided several medicines from their clinical development to their commercialization.LAKE OSWEGO, Ore., May 10, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced the appointment of Robert Figlin, M.D., F.A.C.P. to the Company's Scientific Advisory Board .WASHINGTON, May 9 2012 (AP) -- Shares of Arena Pharmaceuticals Inc. continued to rise Wednesday, a day after federal health regulators issued a surprisingly favorable assessment of the company's previously rejected diet pill.MONTRÉAL, May 9, 2012 /CNW/ - Sanofi Canada announced today that Mozobil (plerixafor), a new treatment for the mobilization of stem cells in patients with non-Hodgkin's Lymphoma (NHL) and multiple myeloma (MM), is now available on the Canadian market.Copenhagen, Denmark, May 9, 2012 / B3C newswire / – Nuevolution A/S today announced that it has received a milestone payment derived from its collaboration with Boehringer Ingelheim.LAKE OSWEGO, Ore., May 9, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced that Mark W. Schwartz, Ph.D., Executive Vice President and Chief Operating Officer, will give a presentation entitled, "Phase II Optimising NeuVax(TM) treatment for HER2 1+ and 2+ (HER2 negative) breast cancer patients: Identifying optimal patient populations for both meeting unmet medical need and optimising clinical trial success," at the Immunotherapy Leaders' Forum 2012 held in Barcelona, Spain.NEW HAVEN, Conn., May 9, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has begun dosing ACH-3102 in a Phase 1 clinical trial. ACH-3102 is Achillion's second generation pan-genotypic NS5A inhibitor being investigated for the treatment of chronic hepatitis C virus (HCV) infection.Singapore, May 9, 2012 - (JCN Newswire) - Researchers at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have developed a miniaturized biochip for investigating the effect of drugs on cancer stem cells (CSCs).Published recently in Nano Today, this new technology could boost the development of more effective cancer drugs.ROCHESTER, Minn. — Rather than stimulating immune cells to more effectively battle cancerous tumors, treatment with the protein interleukin-12 (IL-12) has the opposite effect, driving these intracellular fighters to exhaustion, a Mayo Clinic study has found. The findings appear in the Journal of Clinical Investigation.The study helps explain the negative results of clinical trials testing the treatment's ability to ramp up the body's natural immune response to destroy cancer cells. The study also demonstrates that the same "T cell exhaustion" that plagues specialized immune cells during chronic viral infections also affects cells fighting long bouts of cancer.Reinach, Switzerland, 9 May 2012 – The Annual General Meeting of Evolva Holding SA (SIX: EVE) has approved all proposals put forward by the Board of Directors.BERKELEY, CA -- (Marketwire) -- 05/09/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock, offered at a price to the public of $4.25 per share.MORRISTOWN, N.J., May 9, 2012 (GLOBE NEWSWIRE) -- QPharma, Inc. and Rustici Software have announced that Rustici's SCORM Engine, the leading solution for Sharable Content Object Reference Model compliance, will now be integrated into QPharma's Python LMS online learning and certification system.NEW YORK, May 9, 2012 -- Keryx Biopharmaceuticals, Inc. (KERX) today announced that two abstracts highlighting potential cost savings based on clinical observations from prior clinical trials of Zerenex (ferric citrate), have been accepted for poster presentation at the upcoming National Kidney Foundation (NKF) 2012 Spring Clinical Meetings, taking place May 9-13, 2012, in Washington, DC.YAVNE, Israel, May 9, 2012 (GLOBE NEWSWIRE) -- Clal Biotechnology Industries Ltd. today announces that further analyses of initial data support the achieved primary endpoint of Andromeda Biotech's pivotal phase III clinical study.Geneva, Switzerland, 9 May 2012 - Addex Therapeutics (SIX:ADXN), a leading organization pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved all the proposals of the board of directors at its 2012 annual general meeting (AGM) and that it has completed the organizational changes announced on 13 April 2012.THE WOODLANDS, Texas, May 9, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) today announced it has held a meeting with the Division of Reproductive and Urologic Products (DRUP) to agree upon the registration requirements for the Company's Androxal oral therapy for the treatment of secondary hypogonadism. Repros believes secondary hypogonadism is responsible for over 90% of the incidence of low testosterone in the U.S..Hoboken, NY, May 09, 2012 -- M-Files Inc., the developer of M-Files flexible cloud and on-premise enterprise content management (ECM) solutions, today announced that the Stevens Institute of Technology, a New Jersey-based university specializing in engineering, science, systems and technology management, is utilizing the M-Files Electronic Document Management System (EDMS) solution to provide FDA compliant management of Electronic Records and Electronic Signatures for documents students create during their course project in the “Contemporary Concepts in Pharmaceutical Validation” course in their Pharmaceutical Manufacturing and Engineering Program.WESTON, Mass.--(BUSINESS WIRE)--May 9, 2012 - Today Biogen Idec announced that U.S. and EU regulatory authorities have accepted the company's marketing applications for the review of BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of multiple sclerosis (MS).PARSIPPANY, N.J., May 9, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Mesalamine Delayed-release Tablets, 1.2g. Watson's ANDA product is a generic version of Shire Development LLC's Lialda.
Search the Site
Custom Search
